KYNMOBI™ (apomorphine HCl) was generally well tolerated1,2

Adverse reactions (ARs) occurring in 5% of patients vs placebo in the maintenance phase3a

Nausea 28% 4%
Oral/pharyngeal soft tissue swellingb 15% 0%
Oral/pharyngeal soft tissue pain and paresthesiac 13% 2%
Oral ulceration and stomatitisd 7% 0%
Oral mucosal erythema 7% 4%
Vomiting 7% 0%
Dry mouth 6% 0%
Somnolence 13% 2%
Dizziness 9% 0%
Headache 6% 0%
Rhinorrhea 7% 0%
Fatigue 7% 0%
Fall 6% 2%
Laceration 6% 0%
Hyperhidrosis 6% 4%
Hypersensitivitye 6% 0%

Discontinuation rates3

  • ARs led to discontinuation of KYNMOBI in 9% of patients in the titration phase and in 28% of patients in the maintenance phase compared with 7% of patients on placebo (in the maintenance phase)
  • The most common ARs leading to discontinuation during the maintenance phase were oral/pharyngeal soft tissue swelling, oral mucosal erythema, and nausea/vomiting

References: 1. Olanow CW, Factor SA, Espay AJ, et al; for the CTH-300 Study Investigators. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomized, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19[2]:135-144. 2. Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord. 2016;31(9):1366-1372. 3. Kynmobi. Prescribing information. Sunovion Pharmaceuticals Inc; May 2020.


Thank you for registering at KYNMOBI!

We look forward to telling you more about KYNMOBI, a new medication to treat OFF episodes associated with Parkinson's disease, as it becomes available.

You have been successfully unsubscribed.

Please allow 7-10 days to process your request.